NSG 3029 All Week Discussions Latest SU Week 2 Discussion

For this assignment, make sure you post your initial response to the Discussion Area by the due date assigned.

To support your work, use your course and text readings and articles from the South University Online Library.As in all assignments, cite your sources in your work and provide references for the citations in APA format.

To learn more about qualitative designs, please visit the following website: Qualitative Research Designs

For quantitative designs, please visit the following website:

Research Designs

Start reviewing and responding to the postings of your classmates as early in the week as possible.Respond to at least two of your classmates.Participate in the discussion by asking a question, providing a statement of clarification, providing a point of view with a rationale, challenging an aspect of the discussion, or indicating a relationship between two or more lines of reasoning in the discussion.Cite sources for your responses to other classmates.Complete your participation for this assignment by the end of the week.

Respond to one of the following discussion questions.List all references in APA format.

Discussion Question 1

Based on the following titles of research studies, identify what you believe to be the methodology, design, and rationale of the studies.You also need to provide a rationale for your assertions.

Exploring the rate of seasonal-pattern depression in an Inuit community

Democracy in America

The relationship between compassion fatigue and burnout among critical care nurses

Two drugs for Alzheimer’s show promise

Evaluating technology with student success

Factors that influence weight control among women

The meaning of living with brain injury and stroke 10 years after the injury

Exploring the beliefs of healing among Aborigines

SAMPLE ANSWER

Two drugs for Alzheimer’s show promise

A new class of drugs may help people with Alzheimer’s disease and other forms of dementia, according to two new studies. The drugs, known as BACE inhibitors, work by blocking the activity of an enzyme that helps produce the sticky plaques that clog up the brains of people with Alzheimer’s. In one study, published in the New England Journal of Medicine, patients who took the drug Merck & Co’s MK-8931 for 18 months had slower decline in memory and thinking skills than those who took a placebo. In another study, also published in the New England Journal of Medicine, patients who took Lilly & Co’s solanezumab for 18 months had slower decline in mental function than those who did not receive the drug.

What are the two drugs?

There are currently two drugs approved by the FDA for the treatment of Alzheimer’s disease: Aricept and Namenda. Aricept is a cholinesterase inhibitor, which means it works to increase levels of the neurotransmitter acetylcholine in the brain. This is thought to help with memory and thinking. Namenda is an NMDA receptor antagonist, which means it helps to reduce excess glutamate in the brain. This is thought to help with memory, thinking, and behavior.

What do they show promise for?

The two drugs in question are solanezumab and gantenerumab, both of which are designed to target beta-amyloid plaques in the brain. These plaques are a hallmark of Alzheimer’s disease, and while they are not the cause of the disease, they are believed to play a role in its progression.

So far, both drugs have shown promise in clinical trials. Solanezumab was able to slow the decline of cognitive function in patients with mild Alzheimer’s disease, and gantenerumab was able to reduce amyloid plaques in the brain.

There is still much unknown about these drugs, including whether or not they will be effective in the long-term. However, they offer hope for a potential treatment for Alzheimer’s disease, which currently has no cure.

How do they work?

There are two types of drugs that have shown promise in treating Alzheimer’s disease: cholinesterase inhibitors and memantine.

Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, a neurotransmitter that is essential for memory and learning. There are three cholinesterase inhibitors approved by the FDA for the treatment of Alzheimer’s disease: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne).

Memantine works by blocking the activity of glutamate, another neurotransmitter that is involved in memory and learning. Memantine is approved by the FDA for the treatment of moderate to severe Alzheimer’s disease.

What is the current state of Alzheimer’s research?

There is no cure for Alzheimer’s disease, but there are treatments that can help manage the symptoms. The current state of Alzheimer’s research is focused on finding new ways to treat the disease and improve the quality of life for those affected by it.

Currently, the most promising treatments for Alzheimer’s are drugs that target the beta-amyloid protein. This protein is thought to play a role in the development of Alzheimer’s disease. There are two drugs that are currently in clinical trials that show promise in treating Alzheimer’s disease: solanezumab and aducanumab.

Solanezumab is an antibody that binds to beta-amyloid proteins and prevents them from forming plaques in the brain. Aducanumab is a similar drug, but it works by clearing existing plaques from the brain. Both drugs are still in clinical trials, and it will be several years before we know if they are truly effective at treating Alzheimer’s disease.

In addition to these two drugs, there are many other potential treatments for Alzheimer’s disease in development. Some of these include:

• Drugs that target tau proteins: These proteins are involved in the formation of neurofibrillary tangles, which are another hallmark of Alzheimer’s disease.

• Anti-inflammatory drugs: Inflammation is thought to play a role in the development of Alzheimer

Are there any side effects?

Yes, there are some potential side effects associated with taking these drugs. They include gastrointestinal distress, headaches, and dizziness. Some people have also reported changes in their mood and behavior. It’s important to talk to your doctor about any concerns you may have before starting either of these medications.

When will these drugs be available?

Currently, there are no FDA-approved treatments for slowing the progression of Alzheimer’s disease. However, two drugs that show promise in clinical trials are currently under review by the FDA.

If approved, these drugs would be the first available treatments for Alzheimer’s disease. It is unclear when exactly the FDA will make a decision on these drugs, but it is possible that they could be available within the next few years.

In the meantime, research continues on other potential treatments for Alzheimer’s disease. It is hoped that with continued effort, an effective treatment or cure for this devastating disease will be found soon.

Collepals.com Plagiarism Free Papers

Are you looking for custom essay writing service or even dissertation writing services? Just request for our write my paper service, and we'll match you with the best essay writer in your subject! With an exceptional team of professional academic experts in a wide range of subjects, we can guarantee you an unrivaled quality of custom-written papers.

Get ZERO PLAGIARISM, HUMAN WRITTEN ESSAYS

Why Hire Collepals.com writers to do your paper?

Quality- We are experienced and have access to ample research materials.

We write plagiarism Free Content

Confidential- We never share or sell your personal information to third parties.

Support-Chat with us today! We are always waiting to answer all your questions.